🐂 Not all bull runs are created equal. November’s AI picks include 5 stocks up +20% eachUnlock Stocks

AdAlta to present lead product AD-214 at MPGPCR 2023 pharmacology conference

Published 19/10/2023, 09:39 am
© Reuters.  AdAlta to present lead product AD-214 at MPGPCR 2023 pharmacology conference

AdAlta Ltd (ASX:1AD) has been selected for an extended oral presentation at the 11th Molecular Pharmacology of GPCRs meeting to be held in Melbourne from November 15-17, 2023.

An abstract describing the development and clinically effective dose estimation for the company’s lead product AD-214 has been accepted as a poster and selected for oral presentation at MPGPCR 2023 at the Monash Institute of Pharmaceutical Sciences.

One of four selected

The poster, which will be presented by senior scientist Dr Jason Lynch, is one of just four selected for oral presentation at this important meeting.

MPGPCR 2023 will feature presentations from leading international researchers showcasing new molecular insights, the latest tools and technologies that are changing the understanding of the G-protein coupled receptor (GPCR) function, and translation of basic research into the clinic.

GPCRs are a very important class of drug targets that historically have been difficult for antibodies to address with AD-214 using AdAlta’s i-body® technology to target a GPCR known as CXCR4 with antibody-like precision.

AD-214 targets CXCR4

AD-214 is the only product targeting CXCR4 for fibrotic diseases such as Idiopathic Pulmonary Fibrosis (IPF) and is believed to be the most advanced antibody-like product in active development for IPF, highlighting the power of the i-body® platform to do what antibodies cannot.

The poster ‘Clinical dose estimation for anti-CXCR4 i-body-Fc fusion AD-214 for the treatment of fibrotic disease’ will be at 5.00pm AEST on Wednesday, November 15, 2023.

It will focus on studies and dose simulations supporting the efficacy of AD-214’s target intravenous product and the feasibility of an enhanced subcutaneous product.

The presentation titled ‘Anti CXCR4 i-body-Fc fusion AD-214 for the treatment of fibrotic diseases’ will take place at 12.30pm AEST on Thursday, November 16, 2023.

This will focus on the discovery and characterisation of AD-214, the clinical pharmacology observed in Phase I trials and the clinical dosing simulation that these enabled.

Registrations

Registrations for MPGPCR 2023 close on October 25, 2023, and further details can be found here - https://www.monash.edu/mips/news-events/mpgpcr-2023

Read more on Proactive Investors AU

Disclaimer

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.